Imiglucerase
- Generic Name
- Imiglucerase
- Brand Names
- Cerezyme
- Drug Type
- Biotech
- CAS Number
- 154248-97-2
- Unique Ingredient Identifier
- Q6U6J48BWY
- Background
Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues.
- Indication
For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
- Associated Conditions
- Gaucher Disease, Type 1, Gaucher Disease, Type III
Gensaic and Novo Nordisk Partner to Develop Novel Precision Therapeutics Platform
• Gensaic and Novo Nordisk have formed a strategic collaboration to develop next-generation precision therapeutics, combining Gensaic's innovative delivery platform with Novo's therapeutic expertise.
• The partnership aims to advance novel treatment approaches across multiple therapeutic areas, leveraging advanced drug delivery technologies to enhance therapeutic efficacy and patient outcomes.
• This collaboration represents a significant step forward in precision medicine development, with potential applications in metabolic disorders and other chronic diseases.
Sanofi's Q3 Sales Surge 15.7% Driven by Vaccines and Dupixent; 2024 EPS Guidance Raised
• Sanofi reported a robust 15.7% sales growth in Q3, fueled by strong vaccine sales and the continued success of Dupixent, with sales up 23.8% to €3,476 million.
• Pharma launches, including ALTUVIIIO, Nexviazyme, and Rezurock, saw a significant 67.1% increase, contributing €727 million to the overall sales growth.
• The company's pipeline advanced with four regulatory approvals, including Dupixent for COPD in the US and China, and four positive Phase 3 data readouts, including tolebrutinib for nrSPMS.
• Based on strong Q3 business performance, Sanofi has raised its 2024 business EPS guidance to at least a low single-digit percentage growth at CER.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath